Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|January 27, 2016
SCIEX and the Bioprocessing Technology Institute Announce Partnership
Author(s)Randi Hernandez
The partnership will focus on the identification and analysis of host-cell proteins in biologics.
Advertisement
High-throughput methods of identifying host-cell proteins in biotherapeutics will be the focus of a new partnership between SCIEX and Singapore’s Bioprocessing Technology Institute (BTI), according to a press release from SCIEX on Jan. 26, 2016.
Under the terms of the agreement, SCIEX with provide BTI with analytical mass spectrometry instruments-including the company’s TripleTOF 6600 system, Nano LC system, and proprietary software-to help BTI advance its work on the analysis of contaminating host-cell proteins in biologic drugs. In exchange, BTI will provide SCIEX with data and validation results from their studies.
Singapore’s BTI has been expanding its presence in the biologic space since early 2015. In May 2015, BTI’s Agency for Science, Technology and Research (A*STAR) division partnered with Visterra to develop a neutralizing antibody for the treatment of dengue fever. In July 2015, BTI announced a partnership with Agilent to develop new methods of glycan analysis for large-molecule protein therapeutics.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement